Frontline Treatment and a Geron / J&J carbon copy? Pt. 2

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
kmall
Posts: 753
Joined: Thu Mar 21, 2019 3:57 pm

Frontline Treatment and a Geron / J&J carbon copy? Pt. 2

Post by kmall » Mon Jun 08, 2020 1:10 am

Finally, slightly off topic, Andrew suggested that I take a look at PRM-151 and the ligand trap therapy that could potentially have an effect on fibrosis. I had never heard of this and just had a chance to briefly look into it yesterday. Immediately, I found a PR from Feb. 13, 2020 about a partnership between Promedior – the developer of PRM 151 and Roche which sounded eerily familiar. Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones. - https://www.promedior.com/

Anyway, I’m going to look into this a little further. In the meantime, here is a link on the current clinical trial – P2 which concluded Jan 2020 - if anyone here is interested in giving their take on how this could possibly impact Imet with regards to MF?
PRM 151 – clinical trial - https://clinicaltrials.gov/ct2/show/NCT01981850

I also came across an abstract from August 2019 concerning ligand trap and LR-MDS – not only does it mention Luspatercept, but it states “may represent a new paradigm for anemia treatment in MDS.”…………we know how we’re stacking up against Luspat now, don’t we? – No contest !!
https://pubmed.ncbi.nlm.nih.gov/31203517/

Andrew, I just wanted to congratulate you on your recent mention during the last CC by Dr. Scarlett – my connection was terrible so I was only able to hear bits and pieces – I missed the “shout out.” Kudos to you. Also, you have been giving us a whirlwind of information to digest as of late. Not only is it very well thought out and constructed, but it seems like you have your finger on the pulse of this drug and team which ratchets up discussions here to a level I don’t recall seeing before. A job well done all around. Thanks for providing a service to all of us trying to gain as much insight as possible on all things Imet. Dr. Scarlett just might draft you onto the Board of Directors!! Keep up the good work. -Kmall

Post Reply